DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. PRMRP Research Highlights/News
  3. 2012 Peer Reviewed Medical Research Program

NEWS RELEASE

Released: February 10, 2012

Defense Health Program
Department of Defense Peer Reviewed Medical Research Program
Funding Opportunities for Fiscal Year 2012

The Fiscal Year 2012 (FY12) Defense Appropriations Act provides $50 million (M) to the Department of Defense Peer Reviewed Medical Research Program (PRMRP). The vision of the PRMRP is to improve the health and well-being of all military service members, veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address one of the FY12 congressionally directed topic areas with original ideas that foster new directions in basic science and translational research; novel product development leading to improved therapeutic or diagnostic tools; or clinical trials that address an immediate clinical need. This program is administered by the U.S. Army Medical Research and Materiel Command through the Office of the Congressionally Directed Medical Research Programs (CDMRP).

Congressionally Directed Topic Areas: The FY12 PRMRP will solicit research applications for the following 22 topics areas: Arthritis, Composite Tissue Transplantation, Dystonia, Drug Abuse, Epilepsy, Food Allergies, Fragile X Syndrome, Hereditary Angioedema, Inflammatory Bowel Disease, Interstitial Cystitis, Listeria Vaccine for Infectious Disease, Lupus, Malaria, Nanomedicine for Drug Delivery Science, Neuroblastoma, Osteoporosis and Related Bone Disease, Paget's Disease, Polycystic Kidney Disease, Post-Traumatic Osteoarthritis, Scleroderma, Tinnitus, and Tuberculosis.

Military Relevance: Relevance to the health care needs of the military service members, veterans, and beneficiaries is a key feature of each FY12 PRMRP award mechanism.

The PRMRP is providing information in this pre-announcement to allow investigators time to plan and develop applications. FY 12 PRMRP program announcements and general application instructions for the following award mechanisms are anticipated to be posted on Grants.gov in February and March 2012. Application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Trial Assistant Professor level or above (or equivalent)
  • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area of interest
  • Clinical trial is expected to be initiated within 12 months of award date
  • Maximum of $2.2 million for direct costs (plus indirect costs)
  • Maximum period of performance is 5 years
Discovery Award All Investigators
  • Supports the exploration of a highly innovative new concept or untested theory
  • Projects involving human subjects or specimens will not be supported unless they are exempt under Title 32, Code of Federal Regulations, Part 219, Section 101(b)(32 CFR 219.101[b])
  • Maximum of $125,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 18 months
Investigator-Initiated Research Assistant Professor level or above (or equivalent)
  • Supports research that will make an original and important contribution to the field of research or patient care in the topic area of interest
  • Partnering Principal Investigator option available
  • Clinical trials will not be funded
  • Preproposal submission is required; application submission is by invitation only
  • Maximum of $750,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
Technology/Therapeutic Development Assistant Professor level or above (or equivalent)
  • Supports the development of new diagnostics or therapies that have the potential to make a strong impact on patient care in the topic area of interest
  • Product-oriented
    • Device
    • Drug
    • Clinical guidance/guidelines
  • Clinical trials will not be funded
  • Maximum of $1.5 million for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

All applications must conform to the final program announcements and application instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the program announcements are released.

Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (https://CDMRP.HEALTH.MIL).

Point of Contact: